(NASDAQ: ANNX) Annexon's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Annexon's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast ANNX's revenue for 2026 to be $1,356,070,033, with the lowest ANNX revenue forecast at $886,492,384, and the highest ANNX revenue forecast at $1,865,144,868. On average, 3 Wall Street analysts forecast ANNX's revenue for 2027 to be $13,583,740,359, with the lowest ANNX revenue forecast at $6,813,264,488, and the highest ANNX revenue forecast at $21,942,880,800.
In 2028, ANNX is forecast to generate $38,494,944,359 in revenue, with the lowest revenue forecast at $21,737,714,865 and the highest revenue forecast at $55,252,173,854.